Sort
48,018 grants matching “immunotherapy”
Mechanisms of Murine Turmor Eradication by Immunotherapy
$536,912Philip D Greenberg · University Of Washington · R01 · FY2015 · CA
Delineating Functional Immunity via Image-Guided PET
$536,875Nerissa Therese Viola · Wayne State University · R37 · FY2022 · CA
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
$536,764Naoto T Ueno · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
UCLA Tumor Immunology Institutional Traning Grant
$536,711Michael A Teitell · University Of California Los Angeles · T32 · FY2022 · CA
Mechanisms of Vasomotion-mediated Perivascular Clearance in Cerebral Amyloid Angiopathy
$536,695Steven M Greenberg · Massachusetts General Hospital · R01 · FY2025 · NS
Core 3: Mouse Models Core (MM Core)
$536,694Geoffrey Myles Wahl · Salk Institute For Biological Studies · P01 · FY2025 · CA
Genomics and Functional Characterization of NF1-mutated Lung Cancer
$536,682Eric Collisson · University Of California, San Francisco · R01 · FY2021 · CA
Functional and Therapeutic Significance of PLK4 in Melanoma
$536,631Nihal Ahmad · University Of Wisconsin-Madison · R01 · FY2023 · CA
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation
$536,602Dmitriy Zamarin · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
$536,535Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2017 · CA
Fractionated photoimmunotherapy to harness low-dose immunostimulation in ovarian cancer
$536,528Bryan Quilty Spring · Northeastern University · U01 · FY2025 · CA
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies
$536,497Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2021 · CA
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies
$536,497Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2020 · CA
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies
$536,497Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2022 · CA
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies
$536,497Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2019 · CA
Injectable scaffolds for early detection of immune dysregulation and monitoring response to immunotherapies
$536,496Lonnie D Shea · University Of Michigan At Ann Arbor · U01 · FY2025 · EB
Immunologic Monitoring and Cellular Products Laboratory
$536,490Lisa Helene Butterfield · University Of Pittsburgh At Pittsburgh · P30 · FY2015 · CA
Dendritic Cell Vaccination During Lymphoid Reconstitution
$536,345University Of Southern California · R01 · FY2005 · CA
Deciphering the molecular control of intratumoral dendritic cells
$536,319Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
Deciphering the molecular control of intratumoral dendritic cells
$536,319Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Phosphorylation of TSC2 (S1365) as a novel Regulator of mTORC1 Signaling in T Cells
$536,289Erika L Pearce · Johns Hopkins University · R01 · FY2021 · AI
Loss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system
$536,240Deeann Wallis-Schultz · University Of Alabama At Birmingham · R01 · FY2023 · CA
Immunologic Responses to Cow's Milk Proteins in IgE-mediated Cow's Milk Allergy
$536,169Hugh Sampson · Icahn School Of Medicine At Mount Sinai · U19 · FY2008 · AI
A multi-modular approach for human pluripotent stem cell-based liver regeneration
$536,021Valerie B Gouon-Evans · Boston Medical Center · R01 · FY2023 · DK
Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment
$536,018Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2024 · CA